Article Versions Notes

Corominas J, Sapena V, Sanduzzi-Zamparelli M, Millán C, Samper E, Llarch N, Iserte G, Torres F, Da Fonseca LG, Muñoz-Martínez S, et al. Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma. Cancers. 2021; 13(3):426. https://doi.org/10.3390/cancers13030426

Corominas, Josep, Victor Sapena, Marco Sanduzzi-Zamparelli, Cristina Millán, Esther Samper, Neus Llarch, Gemma Iserte, Ferràn Torres, Leonardo G. Da Fonseca, Sergio Muñoz-Martínez, and et al. 2021. "Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma" Cancers 13, no. 3: 426. https://doi.org/10.3390/cancers13030426

Corominas, J., Sapena, V., Sanduzzi-Zamparelli, M., Millán, C., Samper, E., Llarch, N., Iserte, G., Torres, F., Da Fonseca, L. G., Muñoz-Martínez, S., Forner, A., Bruix, J., Boix, L., & Reig, M. (2021). Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma. Cancers, 13(3), 426. https://doi.org/10.3390/cancers13030426